Compare ResMed Inc. (RMD) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Simon Property Group Inc — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.73B), while Simon Property Group Inc trades at $206.11 (market cap $66.18B). The key difference: Simon Property Group Inc is far larger — about 2.1× ResMed Inc.'s market cap, and Simon Property Group Inc pays the higher dividend (4.35%). Which is the better fit depends on your goals.
| RMD | SPG | |
|---|---|---|
Market Cap | $31.73B | $66.18B |
Sector | Health | Real Estate |
52-Week High | $283.28 | $236.70 |
52-Week Low | $182.82 | $173.35 |
Enterprise Value | $31.08B | $94.63B |
Dividend Yield | 1.2% | 4.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% on the day, with a bearish technical signal and key support at $218. The company reported strong Q4 2026 results, beating EPS estimates at $2.95, and maintains robust profitability with a 26.94% net income margin. Revenue growth remains solid, reaching $5.15B in 2025, though weak 2027 sales guidance has pressured the stock. A dividend of $0.66 is scheduled for payment in September 2026.
Outlook is mixed: strong fundamentals and a consensus price target of $235.70 suggest upside, but bearish technicals and investor lawsuits pose near-term risks. The stock offers value with a P/E of 21.19, yet competitive and regulatory challenges require monitoring for sustained growth.
SPG trades at $211.88, up 1.17% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a Q2 2026 revenue increase of 19.3% and a net income margin of 66.57%, supported by a P/E of 14.95. Recent news includes a $800 million senior notes issuance and the launch of Simon Media Network to monetize mall traffic.
The outlook is mixed; analyst consensus targets $231.82 with 42% buy ratings, but technical indicators suggest near-term pressure. Key risks include high leverage with $24.21B long-term debt and sensitivity to retail real estate cycles. Upside potential hinges on continued leasing strength and effective new media initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
